Isis Pharma Reports Data From Phase 2 Study Of ISIS-APOCIIIRx - Quick Facts

(RTTNews) - Isis Pharmaceuticals Inc. (ISIS) announced data from a Phase 2 study of ISIS-APOCIIIRx in patients with high to severely high triglycerides on stable doses of fibrates. In the study, patients treated with ISIS-APOCIIIRx experienced reductions of up to 70 percent in apolipoprotein C-III and up to 64 percent in triglycerides. Patients treated with ISIS-APOCIIIRx experienced an up to 52 percent increase in high-density lipoprotein cholesterol, and an up to 77 percent reduction in apoC-III-associated very low-density lipoprotein particles.

The Phase 2 study of ISIS-APOCIII­Rx was a double-blind, randomized, placebo-controlled 13-week study designed to assess the safety and activity of ISIS-APOCIIIRx.

Isis Pharma said, in the study, ISIS-APOCIIIRx was found to be generally safe and well tolerated. The most common adverse event was injection site reactions.